Assoc. Prof. Dr. Ismael Lares-Asseff | Pharmacology | Lifetime achievement Award
Assoc. Prof. Dr. Ismael Lares-Asseff, Instituto Politécnico Nacional, CIIDIR Durango, Mexico
Publication Profile
Background and Academic Achievements
Assoc. Prof. Dr. Ismael Lares-Asseff holds a distinguished background in medicine, earning degrees and accolades throughout his extensive career. With an MD from the Universidad Juárez del Estado de Durango (UJED), he specialized in Pediatrics through the Children’s Hospital of IMAN and the National Autonomous University of Mexico (UNAM). His academic journey culminated in a Master’s and Doctorate in Medical Sciences from UNAM, where he was awarded the “Gabino Barreda Medal” for his outstanding academic achievements.
Contributions to Pediatric Research and Clinical Pharmacokinetics
Under the mentorship of Dr. Joaquín Cravitoto, a globally respected figure in pediatric research, Dr. Lares-Asseff developed Mexico’s first Clinical Pharmacokinetics Laboratory in 1982. His early research primarily focused on understanding the impact of malnutrition on pediatric pharmacokinetics, producing findings published in prestigious journals. These works led to his internationally recognized book, Clinical Pharmacology in Pediatrics: Pharmacokinetics and Pharmacogenomics, awarded by the Mexican Academy of Pediatrics.
Conclusion
Assoc. Prof. Dr. Ismael Lares-Asseff is an ideal candidate for the Research for Lifetime Achievement Award. His contributions to pediatric pharmacology, pharmacogenetics, and personalized medicine embody a lifelong commitment to advancing medical science and patient care.
Publication Top Notes
- 🧬 Influence of Age, Gender, and BMI on IV Pharmacokinetics of Buprenorphine in Children Undergoing Orthopedic Surgery, Rivera-Espinosa, L., Vicencio-Rosas, E., et al., Dose-Response, 2024, 0 citations.
- 👨⚕️ Population Pharmacokinetics and Pharmacodynamics of L-asparaginase and Its Impact on Pancreatitis in Leukemia Patients, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Drug and Chemical Toxicology, 2024, 0 citations.
- 💉 Nutritional Status as a Risk Factor for Doxorubicin Cardiotoxicity in Mexican Children with ALL, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Nutrition and Cancer, 2024, 0 citations.
- 🧪 Impact of SNPs and Nutrition on Doxorubicin Pharmacokinetics and Cardiotoxicity in Leukemia Patients, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Journal of Oncology Pharmacy Practice, 2023, 3 citations.
- 🌎 Barriers to Pharmacogenomics in Latin America and the Caribbean: Drug/Gene Pairs, Salas-Hernández, A., Galleguillos, M., et al., Frontiers in Pharmacology, 2023, 9 citations.
- 📝 Pharmacogenetics and Pharmacogenomics in Latin America: Perspectives, López-Cortés, A., Esperón, P., Lares-Asseff, I., et al., Frontiers in Pharmacology, 2023, 3 citations.
- 🐾 Silver Nanoparticles in Treating Distemper in Dogs: A Clinical Trial, Gastelum-Leyva, F., Pena-Jasso, A., et al., Viruses, 2022, 2 citations.
- 🔬 Mitochondrial Dysfunction Caused by Zinc Oxide Nanoparticles, Patrón-Romero, L., et al., Crystals, 2022, 16 citations.
- 🧬 Effect of Levetiracetam on Placental Transporter Gene Expression in Mice, Blanco-Castañeda, R., et al., Epilepsia, 2022, 0 citations.
- ❤️ Genetic Polymorphisms and Doxorubicin Cardiotoxicity in Children with ALL, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Pharmacogenetics and Genomics, 2021, 8 citations.